In a Monday report, analyst John Cheong notes that aside from being a proxy to the premium healthcare space in countries with rapidly growing demand, the group also has a strong track record of building up operations in markets lacking medical-pricing regulations.
SINGAPORE (June 5): Maybank Kim Eng Research is maintaining its “hold” call on IHH Healthcare with a higher price target of RM6.17 ($2) from RM5.62 previously, highlighting the stock as a healthcare leader in the premium hospital segment with a strong brand name.
The counter continues to trade at a premium of 22 times FY17E EV/EBITDA, versus 20 times for its regional peers.
